Open-label RCT in 35 RA patients stable on ultra-low-dose rituximab: s.c. 336 mg vs i.v. 200 mg gave an AUC ratio of 0.99 (90% CI 0.82-1.20; margin 0.8), suggesting non-inferior pharmacokinetics, though AUC uncertainty prevents a firm conclusion.
RCTn = 35
Bovens et al. Subcutaneous versus intravenous ultra-low-dose rituximab in rheumatoid arthritis: a randomized controlled PK-PD non-inferiority trial